Chimeric Therapeutics Ltd (ASX:CHM) has strengthened its management team with the appointment of experienced pharma executive Cassandra Harrison as vice president of Clinical Operations and Data Management.
Harrison joins Chimeric with more than 10 years of experience in clinical operations, compliance and data management.
Looking ahead, the new VP role will focus on leading Chimeric’s successful execution of all clinical program operations as it moves forward with a portfolio of four phase-1 clinical trials.
“Pivotal time for business”
Chimeric CEO and managing director Jennifer Chow said: “We are excited to welcome Cassandra as the vice president Clinical Operations at Chimeric, a newly created but critically important position within our organisation.
“She is a high calibre addition to our management team who will play a key role in advancing our clinical pipeline at this exciting and pivotal time for the business.”
Notable positions
Until recently, Harrison was vice president of Clinical Operations and Data Management at ImmunoGenesis, Inc., an immuno-oncology company, where she built both the clinical operations and data management departments and provided oversight on all aspects of data management and clinical operations.
She also has extensive cell therapy experience from her previous role at Bellicum Pharmaceuticals where she was part of the pioneering team exploring CAR T cell therapies in solid tumours.
At Bellicum she led, managed and implemented organisational resources, and oversaw data management and outsourcing across multiple clinical programs.
Harrison holds active nursing licensures in North Carolina, Massachusetts and Pennsylvania. She also has a Master of Business Administration from Aspen University, Colorado, and a Master of Public Health from Walden University, Minnesota.
About Chimeric
Chimeric Therapeutics is a clinical-stage company with a focus on research related to the usage of cell therapy for the treatment of cancer.
The company is developing CAR T cell therapies for solid tumours based on scientific research conducted by the US CAR T experts at the City of Hope Cancer Centre in Los Angeles.
The CLTX-CAR T technology incorporates chlorotoxin, a peptide derived from scorpion toxin, as a novel CAR tumour recognition domain.
Chimeric recently established a A$30 million equity funding agreement with leading global investor, L1 Capital Global Opportunities Master Fund which will be used to progress the clinical pipeline.